Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | The advantages of allogeneic products derived from healthy donors

LaQuisa Hill • 13 Dec 2021
ASH 2021
B-Cell Lymphoma Lymphoma T-Cell Lymphoma

LaQuisa Hill, MD, Texas Children’s Hospital, Houston Methodist Hospital, Houston, TX, describes the role of allogeneic products in treating B-cell and T-cell lymphomas. Using healthy donor cells to manufacture allogeneic therapies can increase overall quality and expedite treatment in patients. Despite graft versus host disease (GvHD) being a concern, such cases have not been seen in patients. Dr Hill additionally highlights the development of anti-CD37 allogeneic products. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from LaQuisa Hill

1:23
Challenges with administering cellular therapies in patients with T-cell malignancies
LaQuisa Hill • 2 Jun 2023
2:00
Phase I study of CD5 CAR-T therapy manufactured with TKIs in R/R T-ALL
LaQuisa Hill • 2 Jun 2023
2:30
CAR-T cell therapies in T-cell lymphoma and leukemia
LaQuisa Hill • 13 Dec 2021
1:29
CD5.CAR T-cell therapy in patients with T-cell lymphoma
LaQuisa Hill • 13 Dec 2021

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals